Evidence map›Paper›PMID 40299711›Full record

ArticleACS chemical neuroscience2025

Enantiospecific Positive Allosteric Modulation of α4β2 Nicotinic Receptor Subtypes.

Josue Gaona, Pradip K Gadekar, Khaldoun S Abdelwahed, Nataly E Sanchez, Amaya Rolling, Robert Beaudoin, Brent Bill, Andrew T Kerr, Ganesh A Thakur, Ayman K Hamouda

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Josue GaonaDepartment of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.
Pradip K GadekarDepartment of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0002-9129-8812
Khaldoun S AbdelwahedDepartment of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.
Nataly E SanchezDepartment of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.
Amaya RollingDepartment of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.
Robert BeaudoinDepartment of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.
Brent BillDepartment of Biology, The University of Texas at Tyler, Tyler, Texas 75799, United States.
Andrew T KerrCenter for Biomolecular Science and Engineering, US Naval Research Laboratory, Washington D.C. 20375, United States.
Ganesh A ThakurDepartment of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0002-7468-8819
Ayman K HamoudaDepartment of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.ORCID 0000-0001-7819-3074

Funding

Selective Positive Allosteric Modulators of a4b2 Nicotinic ReceptorsR01DA059985 · NIDA · NORTHEASTERN UNIVERSITY · PI CHRISTIE D FOWLER, Ayman K. Hamouda · 2024 to 2026
$2.1M
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons diseaseR16NS129676 · NINDS · UNIVERSITY OF TEXAS TYLER · PI HAMOUDA, AYMAN K. · 2022 to 2025
$588k
NIDA NIH HHS R01 DA059985NINDS NIH HHS R16 NS129676
6 · The paper itself

Abstract

Nicotinic acetylcholine receptors (nAChRs) are integral to brain function, playing critical roles in cognition and reward pathways. Among these, α4β2 nAChRs are key targets for developing therapeutics to address nicotine addiction and cognitive disorders. Here, we report the synthesis, stereochemical resolution, and pharmacological evaluation of GAT2800, a racemic compound identified as a positive allosteric modulator (PAM) of α4β2 nAChRs. Enantiomeric resolution yielded the inactive

Indexed as

Nicotinic AgonistsReceptors, NicotinicAllosteric RegulationAnimalsHumansOocytesPatch-Clamp TechniquesStereoisomerismXenopus laevisNicotinic Agonistsnicotinic receptor alpha4beta2Receptors, Nicotinicchiral separation and X-ray crystallographycognitive disorderscomputational dockingnicotine addictionnicotinic acetylcholine receptorspositive allosteric modulatorstwo-electrode voltage clamp (TEVC)α4β2 nAChRs

Identifiers

PMID40299711
PMCPMC13093463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.